We have added Vivus, Inc. to our evaluated company list. Founded in 1991 and originally focused on treating both male and female sexual dysfunction, the last several years have seen the company develop an obesity treatment, Qnexa, which is now poised to become its flagship product. Vivus is also developing a PDE5 inhibitor, Avanafil, for the treatment of erectile dysfunction (ED), and markets MUSE, a 'break-even' product for the treatment of ED that provides the company with minimal revenue. The company has brought Luramist, a transdermal testosterone spray for the treatment of female sexual arousal disorder (FSAD), through Phase II development but is awaiting a partner to develop it further.

For the full report, please download the PDF version at the top of this page.

For our disclosures, please read the BioMedTracker Research Standards.